Patients with Advanced Thyroid Cancer Containing TRK Fusions May Benefit from Recently FDA-Approved Larotrectinib

Clinical Thyroidology, Volume 31, Issue 2, Page 76-79, February 2019.


http://bit.ly/2GmYoxM